Mitoxantrone

證據等級: L5

預測適應症: 8 個

Mitoxantrone: From Established Antineoplastic Chemotherapy to Upper Aerodigestive Tract Neoplasm

One-Sentence Summary

Mitoxantrone is an anthraquinone antineoplastic agent, structurally related to the anthracyclines, historically used against metastatic breast cancer, acute leukemias, and non-Hodgkin lymphoma. The TxGNN model predicts it may also be effective for Upper Aerodigestive Tract Neoplasm, a prediction supported by 1 registered clinical trial and 20 publications, including several Phase II trials in head-and-neck-region cancers. No Taiwan/US marketing or formal safety-label data are currently available for this drug.

Quick Overview

Item	Content
Original Indication	Not available from TFDA/US license records (0 licenses on file); per literature, mitoxantrone is historically used for metastatic breast cancer, acute leukemias, and non-Hodgkin lymphoma
Predicted New Indication	Upper Aerodigestive Tract Neoplasm
TxGNN Prediction Score	99.78%
Evidence Level	L3 (single-arm Phase II trials + 1 systematic review; no completed RCT)
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed, structured mechanism-of-action data is not currently available for mitoxantrone in this evidence pack (flagged as a High-severity data gap). Based on the literature returned by the same evidence collection, mitoxantrone is described as an anthraquinone antineoplastic agent “with structural similarities to doxorubicin” and “a mechanism of action similar to the anthracyclines” (PMID 3512224) — i.e., a DNA-intercalating topoisomerase II inhibitor. This class of drugs is broadly cytotoxic across proliferating tumor cells and is not tissue-restricted, which mechanistically supports testing in additional solid-tumor indications.

“Upper aerodigestive tract neoplasm” is an umbrella term covering cancers of the oral cavity, pharynx, larynx, and related structures (head and neck, nasopharyngeal, salivary gland, and adenoid cystic carcinomas). The evidence pack shows that this overlaps substantially with the independently-ranked “head and neck cancer” indication (rank 7 in this same evidence pack), which has stronger and more recent trial support (6 registered trials, including ongoing Phase II/III studies of liposomal mitoxantrone in nasopharyngeal carcinoma). This convergence across two independently scored TxGNN predictions strengthens biological plausibility.

Historically, mitoxantrone has already been studied as monotherapy and in combination regimens (with cisplatin, ifosfamide, raltitrexed/5-FU) specifically in head-and-neck-region cancers dating back to the 1980s–2000s, with modest single-agent response rates reported. This existing investigational track record in an anatomically overlapping tumor group is the most direct evidence supporting the TxGNN prediction, rather than a purely novel mechanistic hypothesis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06953739	Phase 3	Not Yet Recruiting	60	Multicenter RCT comparing pegaspargase-based P-GEMD vs. P-Gemox regimens in untreated early-stage non-upper-aerodigestive-tract or advanced-stage extranodal NK/T-cell lymphoma; the exact composition of P-GEMD (whether it includes mitoxantrone) is not specified in the evidence pack.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31324333	2019	Systematic Review	Bulletin du Cancer	Systematic review of systemic treatments (chemotherapy, targeted therapy, immunotherapy) for recurrent/metastatic adenoid cystic carcinoma of the head and neck.
8922205	1996	Phase II Trial	Annals of Oncology	EORTC Head and Neck Cancer Cooperative Group Phase II study of mitoxantrone monotherapy in adenoid cystic carcinoma.
1650529	1991	Phase II Trial	American Journal of Clinical Oncology	Phase II trial of single-agent mitoxantrone (14 mg/m² q3w) in 19 patients with incurable head and neck carcinoma; toxicity mainly mild-to-moderate leukopenia.
11290867	2001	Phase II Trial	Anti-Cancer Drugs	Ifosfamide + mitoxantrone combination in recurrent/metastatic squamous cell carcinoma of the head and neck.
12045460	2002	Phase II Trial	Anti-Cancer Drugs	Mitoxantrone + cisplatin in recurrent/metastatic salivary gland malignancies (14 patients).
1735075	1992	PK/PD Study	Cancer	Pharmacokinetic/pharmacodynamic study of IV mitoxantrone (12–14 mg/m²) in 15 patients with advanced nasopharyngeal carcinoma.
11269736	2001	Phase I Trial	Cancer Chemotherapy and Pharmacology	Phase I study of mitoxantrone + raltitrexed + levofolinic acid + 5-FU in advanced solid tumors, building on prior activity in head and neck/colorectal cancer.
3512224	1986	Review	Drug Intelligence & Clinical Pharmacy	General pharmacology review; notes reported activity of mitoxantrone in head and neck cancer among other tumor types.
39472118	2024	Clinical Study	Chinese Journal of Otorhinolaryngology Head and Neck Surgery	Application of mitoxantrone hydrochloride as a tracer for cervical lymph node/parathyroid identification during thyroid cancer surgery (n=180).
38514342	2024	Clinical Study	Zhonghua Yi Xue Za Zhi	Dual fluorescence imaging (including mitoxantrone tracing) for central lymph node/parathyroid identification in thyroid cancer surgery.

US Market Information

Currently no marketing authorization records are on file — taiwan_regulatory.total_licenses = 0 and market status is “未上市” (Not Marketed).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (anthracenedione/anthraquinone class, topoisomerase II inhibitor structurally related to anthracyclines)
Myelosuppression Risk	High — multiple trial reports across indications describe leukopenia and thrombocytopenia as the major dose-limiting toxicities (e.g., PMID 1650529: “leukopenia was mild, moderate, sev[ere]”; other trials in this evidence pack cite leukopenia/thrombocytopenia as major toxicities)
Emetogenicity Classification	Please refer to the package insert warnings and precautions (not reported in this evidence pack)
Monitoring Items	CBC with differential; liver and renal function; cardiac monitoring (ECG/LVEF) given known anthracenedione-class cardiotoxicity
Handling Protection	Requires cytotoxic drug handling precautions per standard chemotherapy handling regulations

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The literature base (L3: systematic review plus multiple single-arm Phase II trials) shows modest but real single-agent/combination activity of mitoxantrone in head-and-neck-region tumors, and the only registered trial for this specific indication is not yet recruiting. Critically, TFDA warning/contraindication data is a Blocking gap that prevents any S1 safety pre-assessment, and the drug currently has no Taiwan or US marketing authorization.

To proceed, the following is needed:

TFDA (or equivalent international) package insert data — warnings, contraindications, precautions
Confirmed mechanism-of-action data from DrugBank
Drug-drug interaction (DDI) data (current query returned “not_found”)
Monitoring of NCT06953739 as it advances past “Not Yet Recruiting”
Clarification of regimen composition (does P-GEMD include mitoxantrone?) before citing that trial as direct supporting evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.